New Dual-Antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT07266428
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tumors or slow their growth. Participants receive OTP-01 by IV infusion and undergo regular blood tests and scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OTP-01 (a dual antibody targeting PD-1 and VEGFR2)
- What this could lead to
- If successful, this could lead to a new treatment option that shrinks tumors or slows their growth in people with advanced solid cancers.
- What could go wrong
- This is an early-phase trial with only 170 participants, so the drug may not work as hoped or could cause significant side effects. Results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara Oncology Training and Research Hospital
RECRUITINGAnkara, Turkey (Türkiye)
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
-
Cancer Research SA
RECRUITINGAdelaide, Australia
Contact Email: •••••@•••••
-
Centro Gaucho Integrado
RECRUITINGPorto Alegre, 90850-170, Brazil
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, 2050, Australia
Contact Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
Contact Email: •••••@•••••
-
Hospital de Santa-Maria-Centro Hospitalar Lisboa Norte (CHLN)
RECRUITINGLisbon, 1649-036, Portugal
Contact Email: •••••@•••••
-
Linear Clinical Research
RECRUITINGNedlands, 6009, Australia
Contact Email: •••••@•••••
-
START Dublin Early Phase Clinical Trials Unit
RECRUITINGDublin, D07 R2WY, Ireland
Contact Email: •••••@•••••
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Email: •••••@•••••
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Email: •••••@•••••
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?